Yenny Porrata
Psychiatric/Mental Health · Miami, FLNPI 1316453020
Payments from drug & device makers
Across 384 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$900
- Otsuka America Pharmaceutical, Inc.$826
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$707
- Takeda Pharmaceuticals U.S.A., Inc.$618
- Axsome Therapeutics, Inc.$519
- plus $2K from 10 others
What the payments were for
- Food & beverage$7,074100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 122 | $1,986 |
| Lundbeck LLC | 40 | $900 |
| Otsuka America Pharmaceutical, Inc. | 51 | $826 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $707 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $618 |
| Axsome Therapeutics, Inc. | 29 | $519 |
| Almatica Pharma LLC | 20 | $387 |
| Vanda Pharmaceuticals Inc. | 11 | $265 |
| Alkermes, Inc. | 14 | $249 |
| Neurocrine Biosciences, Inc. | 8 | $223 |
| Johnson & Johnson | 5 | $120 |
| Teva Pharmaceuticals USA, Inc. | 5 | $98 |
| Sunovion Pharmaceuticals Inc. | 6 | $72 |
| Tris Pharma Inc | 2 | $46 |
| Tempus AI, Inc | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
How this compares
$7,080 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 68 | $105,222 |
| Risperdal ConstaRisperidone Microspheres | 13 | $36,439 |
| TrintellixVortioxetine Hydrobromide | 66 | $33,558 |
| VraylarCariprazine Hcl | 19 | $26,745 |
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $21,486 |
| CaplytaLumateperone Tosylate | 12 | $19,918 |
| Lurasidone Hcl | 43 | $15,868 |
| Paliperidone ErPaliperidone | 11 | $12,104 |
| Aripiprazole | 76 | $8,149 |
| BelsomraSuvorexant | 17 | $7,525 |
| Quetiapine Fumarate | 283 | $3,567 |
| Chlorpromazine Hcl | 13 | $3,492 |
| Trazodone Hcl | 480 | $3,464 |
| Duloxetine Hcl | 107 | $2,701 |
| Escitalopram Oxalate | 300 | $2,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $826 | $105,22268 claims |
| Johnson & JohnsonRisperdal Consta | $120 | $36,43913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $618 | $33,55866 claims |
| AbbVieVraylar | $1,986 | $26,74519 claims |
| Axsome Therapeutics, Inc.Auvelity | $519 | $21,48627 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $707 | $19,91812 claims |
| Almatica Pharma LLCSertraline Hcl | $387 | $1,451386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Miami
- Carlos LarrauriMiami$23K
- Sandra Pelaez-MurseyMiami$20K
- Rolando Gonzalez AriasMiami$18K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.